Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q2-2022 Dermatology Update

Skip to the end of the Expertise Menu

Q2-2022 Dermatology Update

Dermatology deal activity continued its rebound towards 2018 and 2019 levels after a relatively slow 2020 and 2021, primarily driven by strategic add on transactions and secondary buyouts. The quarter saw a number of notable transactions that will have a meaningful impact on the dermatology space, particularly, as it relates to M&A. One such deal was Sheridan Capital’s exit of Dermatologists of Central States (DOCS) to private equity firm SkyKnight Capital, the third secondary transaction in as many quarters. Another landmark deal occurring this quarter was the merger between West Dermatology and Platinum Dermatology Partners, two sizable, regional platforms spanning multiple states and over 100 providers. Provident expects transaction volume and valuations to remain elevated, but is tracking macroeconomic factors that may ultimately impact dealmaking in the quarters to come.

To print and download the full Dermatology report, please click below…

[holo_button icon=”/wp-content/uploads/2022/07/Q2-2022-Dermatology-Newsletter-vF.pdf” link=”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]

 

Sources: SEC Filings; Company Press Releases, and Reports; IBISWorld; Capital IQ; PHP Estimates and Research. This document has been compiled with publicly available information. Provident Healthcare Partners, LLC makes no guarantee of its accuracy or completeness. No data or statement should be construed to be a recommendation for the purchase, sale, or retention of any security.